United States · FDA National Drug Code directory
Inluriyo
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 0002-1717_d4c7332d-4da7-4d70-8813-4cecd53fff2a
- Product NDC
- 0002-1717
- Form
- TABLET, FILM COATED
- Composition / generic term
- imlunestrant
- Labeler
- Eli Lilly and Company
- Marketing category
- NDA
- Marketing start / end (source format)
- 20250925
- Source listing expiry
- 20271231
Source-listed ingredients
- IMLUNESTRANT — 200 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 28 TABLET, FILM COATED in 1 BOTTLE (0002-1717-28) · 0002-1717-28
- 56 TABLET, FILM COATED in 1 BOTTLE (0002-1717-56) · 0002-1717-56
- 56 TABLET, FILM COATED in 1 BOTTLE (0002-1717-61) · 0002-1717-61
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →